Route 92 Medical Alleges Patent Infringement Against Q'Apel Medical
Route 92 Medical, Inc., known for its innovative solutions in medical technology, has initiated a patent infringement lawsuit against Q'Apel Medical. This legal action reflects the growing importance of protecting intellectual property in the medical technology sector.
The Foundation of the Patent Suit
The lawsuit centers around the infringement of five U.S. patents that safeguard the Tenzing delivery catheter, a product that has become integral in neurovascular interventions. The complaint was officially filed in the United States District Court for the District of Delaware.
CEO's Statement on Innovation and Legal Action
Tony Chou, the CEO of Route 92 Medical, emphasized the need to defend their innovations. He stated, "Route 92 Medical has reinvented neurovascular intervention. Our growing sales are a testament to the superiority of our solutions. As our success continues, it’s expected that others will attempt to replicate the features found in our Tenzing catheter and other products. However, with an extensive portfolio of over 100 patents, we will defend our intellectual property vigorously."
The Significance of the Tenzing Delivery Catheter
Since its clinical introduction in 2019, the Tenzing delivery catheter has been protected by a robust global patent portfolio, including 23 U.S. patents. This catheter features a uniquely tapered tip that significantly minimizes the ledge effect and enhances atraumatic tracking through the neurovasculature. This design enables consistent navigation to cerebral targets, eliminating the need for a microcatheter.
Advancements in Neurovascular Solutions
Available in three sizes, Tenzing delivery catheters work in tandem with Route 92 Medical's HiPoint and FreeClimb catheters, creating an integrated system that improves the effectiveness of neurovascular procedures. Clinical assessments have affirmed the performance of these devices through ten independent, peer-reviewed studies that cater to various vessel sizes and device lengths.
Commitment to Protecting Innovations
Route 92 Medical recognizes that ongoing innovation is crucial for success in the medical technology field. To reinforce this, the company has been actively expanding its patent portfolio. Recently, they secured additional patents for products associated with their Monopoint family, which includes the Tenzing delivery catheters.
Clinical Investigations and Future Directions
The company has recently concluded the enrollment phase of a significant clinical investigation focused on the Tenzing delivery catheter within their Monopoint Reperfusion System. This ambitious clinical trial, entitled the SUMMIT MAX clinical trial, includes 250 patients and aims to analyze the safety and efficacy of the HiPoint 88 reperfusion catheter used alongside Tenzing 8 delivery catheters compared to other large-bore reperfusion systems.
About Route 92 Medical, Inc.
Route 92 Medical is driven by the mission to enhance outcomes for patients undergoing neurovascular intervention through advanced engineering and innovative designs. Founded by physicians, the company collaborates with top neurovascular clinicians to tackle critical challenges in the field, delivering distinct solutions that ensure clinical success.
Frequently Asked Questions
What prompted Route 92 Medical to file a lawsuit?
The lawsuit was filed against Q'Apel Medical for allegedly infringing on multiple U.S. patents relating to the Tenzing delivery catheter.
What is the Tenzing delivery catheter?
It is a specialized medical device designed to improve neurovascular interventions by reducing complications and enhancing navigation through neurovasculature.
How many patents protect the Tenzing delivery catheter?
It is protected by a global portfolio of over 100 patents, including 23 specifically in the United States.
What is the SUMMIT MAX clinical trial?
This trial involves 250 patients and aims to evaluate the Tenzing delivery catheter's safety and efficacy in neurovascular procedures.
Who can be contacted for more information?
Gwen Gordon from Gwen Gordon PR can be reached via email at Gwen@gwengordonpr.com for any media inquiries.
